Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AMAR NASDAQ:BNTC NASDAQ:INM NASDAQ:INSY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMARAmarillo Biosciences$0.00$0.05▼$1.97$25.24M-0.0618,253 shs6,100 shsBNTCBenitec Biopharma$13.70-1.6%$12.57$8.20▼$17.15$365.41M0.4336,063 shs57,452 shsINMInMed Pharmaceuticals$2.36+1.7%$2.38$1.72▼$8.27$4.65M0.2945,203 shs194,669 shsINSYINSYS Therapeutics$23,687,640.18$0.14▼$11.65$21.71M3.219.52 million shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMARAmarillo Biosciences0.00%0.00%0.00%0.00%0.00%BNTCBenitec Biopharma-1.58%+2.70%+7.79%-8.30%+63.10%INMInMed Pharmaceuticals+1.72%+8.76%+2.61%-5.98%-54.14%INSYINSYS Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMARAmarillo Biosciences$0.00$0.05▼$1.97$25.24M-0.0618,253 shs6,100 shsBNTCBenitec Biopharma$13.70-1.6%$12.57$8.20▼$17.15$365.41M0.4336,063 shs57,452 shsINMInMed Pharmaceuticals$2.36+1.7%$2.38$1.72▼$8.27$4.65M0.2945,203 shs194,669 shsINSYINSYS Therapeutics$23,687,640.18$0.14▼$11.65$21.71M3.219.52 million shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMARAmarillo Biosciences0.00%0.00%0.00%0.00%0.00%BNTCBenitec Biopharma-1.58%+2.70%+7.79%-8.30%+63.10%INMInMed Pharmaceuticals+1.72%+8.76%+2.61%-5.98%-54.14%INSYINSYS Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMARAmarillo Biosciences 0.00N/AN/AN/ABNTCBenitec Biopharma 3.13Buy$24.8081.02% UpsideINMInMed Pharmaceuticals 0.00N/AN/AN/AINSYINSYS Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest INSY, BNTC, INM, and AMAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/16/2025BNTCBenitec BiopharmaOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$35.00 ➝ $29.007/7/2025BNTCBenitec BiopharmaTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMARAmarillo Biosciences$20K0.00N/AN/A($0.03) per share0.00BNTCBenitec Biopharma$80K4,495.31N/AN/A$4.68 per share2.93INMInMed Pharmaceuticals$4.60M1.03N/AN/A$20.64 per share0.11INSYINSYS Therapeutics$82.08M0.00N/AN/A($0.58) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMARAmarillo Biosciences-$1.45MN/A0.00N/AN/A-41,453.98%N/A-574.29%N/ABNTCBenitec Biopharma-$21.75M-$1.51N/AN/AN/AN/A-38.26%-35.71%9/25/2025 (Estimated)INMInMed Pharmaceuticals-$7.68M-$12.09N/A∞N/A-168.87%-107.93%-82.97%9/26/2025 (Estimated)INSYINSYS Therapeutics-$124.51M-$1.39N/AN/AN/A-346.61%-1,430.37%-64.04%N/ALatest INSY, BNTC, INM, and AMAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q4 2025BNTCBenitec Biopharma-$0.24N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMARAmarillo BiosciencesN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/AINMInMed PharmaceuticalsN/AN/AN/AN/AN/AINSYINSYS TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMARAmarillo BiosciencesN/A0.030.07BNTCBenitec Biopharma0.0114.8014.80INMInMed Pharmaceuticals0.063.493.04INSYINSYS TherapeuticsN/A0.540.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMARAmarillo BiosciencesN/ABNTCBenitec Biopharma52.19%INMInMed Pharmaceuticals20.12%INSYINSYS Therapeutics14.93%Insider OwnershipCompanyInsider OwnershipAMARAmarillo Biosciences34.35%BNTCBenitec Biopharma1.30%INMInMed Pharmaceuticals1.43%INSYINSYS Therapeutics65.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMARAmarillo Biosciences242.07 millionN/ANot OptionableBNTCBenitec Biopharma2026.25 million25.91 millionNo DataINMInMed Pharmaceuticals102.00 million1.97 millionNot OptionableINSYINSYS Therapeutics22674.57 millionN/AOptionableINSY, BNTC, INM, and AMAR HeadlinesRecent News About These CompaniesMassachusetts collects $48M restitution for opioid schemeSeptember 17 at 8:59 PM | wwlp.comWLitigation Department of the Year Finalist: Reid Collins & TsaiSeptember 15 at 9:51 AM | law.comLFederal Indictment Against NJ Doctor Collapses in Stunning DOJ Reversal, as Obtained by Health Law AllianceMay 21, 2025 | morningstar.comMLarge Granular Lymphocyte Leukemia Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsightApril 23, 2025 | theglobeandmail.comCarcinoid Tumor Syndrome Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsightApril 15, 2025 | theglobeandmail.comMcKinsey & Company to pay $650 million for role in opioid crisis while executives avoid trialsDecember 14, 2024 | iowapublicradio.orgIRap video is latest evidence in Insys trialOctober 20, 2024 | pharmaphorum.comPInsys settles opioid kickback charges in US, paying out $225mOctober 3, 2024 | pharmaphorum.comPAlly Financial Inc. (ALLY): Among the Dividend Giants with Lowest Short Interest in 2024September 25, 2024 | msn.comARS Pharmaceuticals: A Decent Bet For Upside After Neffy ApprovalSeptember 6, 2024 | seekingalpha.comFeds order Ohio physician to pay $4.7M for illegal opioid prescriptionsAugust 6, 2024 | beckersasc.comBMore than half a billion opioid pills in 14 years: How prescriptions contributed to a crisis in BaltimoreAugust 3, 2024 | msn.comInsys Founder Must Return $5.9 Million Paid For Criminal DefenseAugust 1, 2024 | news.bloomberglaw.comNHow well did Singapore Airlines handle the aftermath of turbulence terrorMay 23, 2024 | travelweekly.com.auTHorror On Singapore Airlines: The Lasting Damage Of A CrisisMay 22, 2024 | bandt.com.auBPetty politics blocks Iowa’s opioid responseMay 14, 2024 | thegazette.comTAldeyra Therapeutics, Inc. (ALDX)May 7, 2024 | finance.yahoo.comHow Sam Bankman-Fried’s 25 Year Sentence Stacks Up Against Other Billionaire, Ex-Billionaire ConvictsMarch 29, 2024 | forbes.comPort Clinton man sentenced for illegal dispensing narcoticsMarch 15, 2024 | msn.comOhio physician sentenced to prison for illegal opioid distributionMarch 14, 2024 | beckersasc.comBNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 20253 Big Dividend Hikes Hit the Market—1 Just Doubled Its PayoutBy Leo Miller | September 8, 2025Tencent Music Stock Outshines Spotify as China’s Music GiantBy Leo Miller | August 31, 2025INSY, BNTC, INM, and AMAR Company DescriptionsAmarillo Biosciences OTCMKTS:AMARAmarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.Benitec Biopharma NASDAQ:BNTC$13.70 -0.22 (-1.58%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$13.71 +0.01 (+0.07%) As of 09/17/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.InMed Pharmaceuticals NASDAQ:INM$2.36 +0.04 (+1.72%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$2.35 -0.01 (-0.64%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.INSYS Therapeutics NASDAQ:INSYInsys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? The Side of Rate Cuts Nobody Is Telling You About Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Dave & Buster’s Stock: Is Now the Time to Make a PLAY? Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
